Agonist-induced rigid body motion of transmembrane (TM-) helices has been established as a unifying mechanism in the activation of the G-protein-coupled receptors. In attempts to measure specific conformational transitions during the activation of the type 1 receptor for angiotensin II (AT 1 ), we found a decrease in accessibility of Cys 76 in the second TM helix suggesting that the orientation of TM2 is altered (Miura and Karnik, J. Biol. Chem. 277: 24299-24305, 2002). Now we provide evidence that the TM2 helical movement plays a role in regulating the activated-state of the AT 1 receptor and this role may involve an interaction between TM2 and TM7. Alanine substitution of native Cys 296 in TM7 leads to increased accessibility of Cys 289 and diminished response to bound agonist. Both effects of the C296A mutation are suppressed when combined with F77A and N111G mutants. The TM7 conformation and the sensitivity of Cys 289 altered by C296A mutation is suppressed by the F77A mutation in TM2 in order to salvage function. We show that the F77A mutant alters orientation of both TM2 and TM7 but does not induce constitutive activity in suppressing the C296A mutant-effects. Thus, interaction of TM2 and TM7
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Receptor Page 4 ethylaminoacetate (MTSEA) derivatization. This provided the first evidence of TM2 helical movement during AT 1 receptor activation. An exhaustive mapping of conformational changes in other helices was, however, hampered because the MTSEA reactivity of the remaining native Cys residues is not known.
Therefore, we reasoned that the construction of an AT 1 receptor CYS -mutant that lacks all free Cys residues would be a useful template for mapping the conformational changes in all TM helices. Hence, we constructed and evaluated single or combinatorial replacements of free Cys residues in the AT 1 receptor. We unexpectedly discovered that substitution of native Cys 296 induces a change in the orientation of TM7, accompanied with functional defects. We show here that both effects induced by C296A mutation are abolished in a mutant located in the TM2. Taken together, these findings expose a critical role of TM2-TM7 interaction in coupling helical movements to G protein-activation. 
Mutagenesis and Expression of the AT 1 Receptor and Membrane Preparation-
The synthetic rat AT 1 receptor gene, cloned in the shuttle expression vector pMT-2, was used for expression and mutagenesis, as described in our earlier studies (7) . To express the AT 1 added and incubation continued for another 45 min at 37 °C. At the end of incubation, the medium was removed, and the total soluble IP was extracted from the cells by the perchloric acid extraction method, as described previously (7) . The values represent the mean ± S.E.M. of three to four independent determinations.
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RESULTS AND DISCUSSION
C296A mutation Alters Accessibility of Native Cystein(s) to MTSEA-Exposure of native Cys
residues to water-accessible ligand pocket was measured by employing a highly reactive, sulfhydrylspecific reaction with MTSEA. Water-exposed Cys residues ionize and react a billion times faster with MTSEA which is > 3000-fold more soluble in water than membrane (7) (8) (9) (10) Table 1 ). The affinity of these mutants was not significantly different from that of the WT receptor for the remaining free Cys residues are not involved (7).The C289A mutant consistently displayed reduced sensitivity to MTSEA, but the magnitude of its reactivity is very small. In contrast, both the magnitude and rate of initial reaction with the MTSEA + was enhanced in the C296A mutant receptor suggesting that this mutation may have perturbed the conformation of the receptor ( Fig. 2A & B) . Competition binding studies with the AT 1 receptor-selective nonpeptide antagonist losartan revealed a 11-fold reduction of affinity for C296A compared to the WT receptor. Substitution of Cys 296 with Gly, Ile and Phe also reduced the affinity for losartan (Table1). These mutants also displayed reduced coupling to IP production. Previous mutagenesis studies have indicated that TM7 plays an important role in nonpeptide antagonist-selectivity and signal activation (6) . Based on these observations, we speculate that C296A mutation perturbs receptor conformation leading to increased accessibility of one or more native Cys residues. C76A/C289A/C296A, C76A, C289A and C296A indicates that the remaining 50% inhibition is consistent with acquired reactivity of Cys 289 in these mutants (Fig. 2C) . The analysis indicates that the C296A mutation induced an increase in the accessibility of Cys 289 without altering the accessibility of 
Reaction of the TM7 Residue, Cys
The C296A-induced Accessibility of Cys 289 is Masked by the F77A Mutation in TM2-
Pharmacological evidence for a specific interaction between TM2 and TM7 in the AT 1 receptor was reported in an earlier study (11). Consistent with this suggestion, the AT 1 receptor molecular-model also indicated that the TM7 region containing the Cys 296 interacts extensively with TM2. Therefore, we looked for compensatory mutations in the TM2 helix and found that Ile, Cys Ala and Gly substitutions of Furthermore, the change in MTSEA-reactivity was accompanied by an increase of affinity for losartan and restoration of agonist-induced IP stimulation in comparison to the C296A mutant ( Table 1) .
Reactivity of other native Cys residues did not change (Fig. 2D) . Thus, the properties of C77A/C296A mutant are more "wild-type-like" than "F77A-like" or "C296A-like". Fig. 3 ). We next evaluated these mutation-induced effects on the constitutive activity of the N111G receptor.
Constitutive activation results from loss of constraint i.e. a lowering of thermodynamic barrier for conformational changes essential for receptor-activation (5). 
